Codexis Inc, Merck deal

Codexis granted Merck a non-exclusive, worldwide license to use Codexis’ CodeEvolver technology to develop custom-designed enzymes for use in manufacturing Merck therapeutics. Codexis will receive $5 million up front and an additional $13 million in technology transfer milestones, which is expected to occur in the next two years. Codexis is also eligible to receive $15 million for each product developed using the technology for a 10-year period. ...